CAMBRIDGE, MA - Hyperion Catalysis International Inc. (Hyperion) has concluded a patent license agreement with Bayer MaterialSciences AG (BMS), a Bayer Group company. In exchange for certain payments, the agreement provides that BMS will be able to sell its Baytubes® carbon nanotubes for use within a defined field under Hyperion’s extensive patent portfolio. The license agreement will help BMS to continue to grow its position as one of the world’s leading carbon nanotube suppliers by providing its customers access to additional applications for BMS’s carbon nanotube-based products.

David M. Wohlstadter, Hyperion’s Vice President of Business Development, stated, “We are quite pleased to have entered into this arrangement with BMS. This license with BMS will further leverage Hyperion’s broad patent portfolio and capitalize on the ever-increasing demand for carbon nanotubes. We feel BMS is well poised to serve and help increase this demand, while Hyperion remains committed to expanding its own sales and providing its customers with the highest quality carbon nanotube-based products.”

Hyperion’s flagship FIBRIL™ technology is a conductive, multi-walled carbon nanotube, which is based on the pioneering work in the field by Dr. Howard G. Tennent. Hyperion, which is headquartered in Cambridge, MA, has been manufacturing and selling its FIBRILTM carbon nanotubes for a wide range of applications since 1983. Hyperion has devoted substantial resources to developing, improving and patenting the technology related to the manufacture and use of carbon nanotubes. Hyperion currently has hundreds of issued patents and patent applications covering the production and use of carbon nanotubes. Hyperion supplies its FIBRIL nanotubes, pre-mixed, in a range of matrices. These nanotube composites are in commercial use in a number of fields including automotive and electronics. The FIBRIL nanotubes are used to impart electrical conductivity and other benefits that are related to the unique structure of the nanotubes.